Table 1 Ongoing clinical trials with ICIs in sarcoma
From: Is immunotherapy in the future of therapeutic management of sarcomas?
NCI trial number | Drug | Type of sarcoma | Phase | Status |
|---|---|---|---|---|
NCT02406781 | Pembrolizumab + Metronomic Cyclophosphamide | Advanced sarcomas (Osteosarcoma Leiomyosarcoma + Undifferentiated + soft tissue sarcoma) | II | Recruiting |
NCT03123276 | Pembrolizumab + gemcitabine | Leiomyosarcoma and Undifferentiated Pleomorphic sarcoma | I/II | Recruiting |
NCT03338959 | Pembrolizumab + Radiation Therapy | Soft tissue sarcoma | I/II | Recruiting |
NCT03092323 | Pembrolizumab with radiotherapy, followed by surgical resection versus radiotherapy | Soft tissue sarcoma | II | Recruiting |
NCT03069378 | Pembrolizumab + talimogene laherparepvec (T-VEC) | Advanced sarcomas | II | Recruiting |
NCT03056001 | Pembrolizumab + doxorubicin | Soft tissue sarcoma | II | Active, not recruiting |
NCT03126591 | Pembrolizumab + Olaratumab | Soft tissue sarcoma | I | Active, not recruiting |
NCT02636725 | Pembrolizumab + axitinib | Alveolar soft + soft tissue sarcoma | II | Active, not recruiting |
NCT03414229 | Pembrolizumab + Epacadostat | Sarcoma | II | Active, not recruiting |
NCT03899805 | Pembrolizumab + Eribulin | Liposarcoma Leiomyosarcoma Undifferentiated Pleomorphic sarcoma | II | Recruiting |
NCT03469804 | Pembrolizumab | Kaposi sarcoma | II | Recruiting |
NCT02888665 | pembrolizumab + doxorubicin | Sarcoma | II | Active, not recruiting |
NCT03123276 | Pembrolizumab + gemcitabine | Leiomyosarcoma and Undifferentiated Pleomorphic Sarcoma | I/II | Recruiting |
NCT03013127 | Pembrolizumab | Osteosarcoma | II | Recruiting |
NCT03219671 | Nivolumab and Ipilimumab | Classic Kaposi sarcoma | II | Recruiting |
NCT03886311 | Nivolumab + Talimogene laherparepvec + Trabectedin | Sarcoma | II | Recruiting |
NCT03282344 | Nivolumab + NKTR-214 | Metastatic and/or locally advanced osteosarcoma | II | Active, not recruiting |
NCT04118166 | Nivolumab + Ipilimumab + Cryotherapy | Soft tissue sarcoma | II | Recruiting |
NCT04095208 | Nivolumab + Relatlimab | Soft tissue sarcoma | II | Recruiting |
NCT03590210 | Nivolumab + Trabectedin | Metastatic soft tissue sarcoma | II | Recruiting |
NCT04535713 | Nivolumab, Gemcitabine, Doxorubicin, Docetaxel | Advanced sarcoma | II | Not recruiting yet (Sep 2020) |
NCT03277924 | Nivolumab + sunitinib | Advanced soft tissue and bone sarcomas | I/II | Recruiting |
NCT03138161 | Trabectedin, Ipilimumab and Nivolumab | Soft tissue sarcoma | I/II | Recruiting |
NCT03190174 | Nivolumab and ABI-009 (mTOR inhibitor) | Advanced sarcoma | I/II | Recruiting |
NCT02982486 | Nivolumab + Ipilimumab | Sarcoma | II | Not recruiting |
NCT04339738 | Paclitaxel with and Without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma | Soft tissue sarcoma | II | Recruiting |
NCT04165330 | Nivolumab + AL3818 (anlotinib) | Metastatic and advanced sarcoma | I/II | Recruiting |
NCT03628209 | Nivolumab or Nivolumab and Azacitidine | Osteosarcoma | I/II | Recruiting |
NCT04149275 | Nivolumab + cabozantinib + ipilimumab | Carcinosarcomas (ovary, uterus, vagina) | II | not recruiting yet |
NCT02428192 | Nivolumab in combination with ipilimumab | Advanced leiomyosarcoma of the uterus | II | Active, not recruiting |
NCT03548428 | Atezolizumab + radiation | Sarcoma | II | Recruiting |
NCT04216953 | Atezolizumab + cobimetinib (MEK inhibitor) | Advanced and/or Metastatic soft Tissue sarcoma | I/II | Recruiting |
NCT03474094 | Atezolizumab + radiotherapy | Soft tissue sarcomas | II | Active, not recruiting |